The aim of the study is to collect, under daily practice conditions, clinical data on the
safety profile and the efficacy of a new formulation of alfuzosin administered once daily in
patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia
(BPH).
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
Completed
Sanofi
Phase 4
2004-03-01
To collect under daily practice conditions, clinical data on the changes of sexual function
when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with
lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy
Clinical Trial in Males With BPH (Enlarged Prostate)
Completed
Sanofi
Phase 3
2001-05-01
A study to determine the effect on prevention of Acute Urinary Retention (inability to
urinate) in males with an enlarged prostate, also known as BPH.
- Free study-related medical care provided.
The primary objective of this randomized clinical trial is to determine the efficacy and
safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle
ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin
and finasteride.
The primary objective of this randomized clinical trial is to determine the efficacy and
safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle
ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin
and finasteride.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.